Clinical Trial Update: A Phase II Study of SYHA1813 for Recurrent or Progressive High-Grade Meningioma [Phase 2]

View source ↗

Summary

Phase II study of SYHA1813 for recurrent or progressive high-grade meningioma is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningioma

Drugs mentioned

• SYHA1813

Snippet

Sponsor: Shanghai Runshi Pharmaceutical Technology Co., Ltd | Conditions: Recurrent or Progressive High Grade Meningioma | Phase 2 | Status: NOT_YET_RECRUITING